Search
Bacampicillin
go.drugbank.com/drugs/DB01602ApprovedWithdrawnIt is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.
Products: BACAMPICILLINA MYLAN GENERICSRoquinimex
go.drugbank.com/drugs/DB11366ExperimentalIts effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.
Propanoic acid
go.drugbank.com/drugs/DB03766ApprovedInvestigationalVet approvedWithdrawnSodium propionate was previously approved in Canada as an active ingredient in Amino-Cerv (used to treat inflammation or injury of the cervix).
Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigationalIt presents selectivity against the mutant forms of EGFR compared to the wild-type.
Clocortolone
go.drugbank.com/drugs/DB00838ApprovedClocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
Dehydroascorbic acid
go.drugbank.com/drugs/DB08830ExperimentalCurrently dehydroascorbic acid is an experimental drug with no known approved indications. … This reaction is reversible, but dehydroascorbic acid can instead undergo irreversible hydrolysis to 2,3-diketogulonic acid.
ATX-101
go.drugbank.com/drugs/DB05780InvestigationalDeoxycholic acid is a naturally occurring bile acid produced by the liver as one of several end products of cholesterol metabolism.
Clofibrate
go.drugbank.com/drugs/DB00636ApprovedWithdrawnA fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)
Ardeparin
go.drugbank.com/drugs/DB00407ApprovedWithdrawnIts molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.
Ropinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous
Products: ROPINIROLO DOC GENERICI, ROPINIROLO MYLAN GENERICS